I now believe anything could happen … now if it were to happen...

First 11683 Last

Share
Profile

Follow
Wilba32

6,948 Posts.

1527

25/09/21

20:50

Post #: 56349862
Share

Originally posted by Mani86: ↑

Copied
Interesting Case Study . Can something like this happen for Mesoblast? see below

In stunning reversal, FDA clears Sarepta DMD drug it rejected 4 months ago
by Angus Liu

The FDA’s attitude toward Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) therapies is nothing short of dramatic. In just four months, the agency shocked industry watchers twice, first with a rejection and now a reversal for the biotech’s Exondys 51 follow-on.

Out of nowhere, the agency Thursday granted accelerated approval to Sarepta’s Vyondys 53 (golodirsen), a drug it turned down in August for safety reasons. The go-ahead covers about 8% Duchenne patients whose dystrophin gene bears a certain mutation amenable to exon 53 skipping.

While the FDA didn’t elaborate on the sudden change of course, Sarepta said it had launched a formal dispute resolution request after receiving the agency's complete response letter (CRL) detailing its reasons for the rejection. Sarepta worked with Peter Stein, director of the FDA's Office of New Drugs, to resolve the concerns raised in that CRL.

In August, a stunned Sarepta said the FDA had rejected Vyondys 53 for the risk of infection linked to intravenous infusion ports and for kidney toxicity seen only in animal studies. Analysts suspected at the time that the agency had changed its standards on using dystrophin as a surrogate marker for approval. DMD patients lack dystrophin, a protein that helps maintain the structure of skeletal muscle fibers, due to missing exons in the DMD gene.

Controversy erupted in 2016 when Sarepta’s Exondys 51 won an FDA thumbs-up based on dystrophin data without showing actual clinical benefits such as improvement on disease progression. Opinions were split even within the FDA; in fact, two officials who'd opposed the green light decided to retire. In contrast, European regulators shot down Exondys 51 last September—for the second time.

Like Exondys 51, Vyondys 53 was approved based only on dystrophin production “that is reasonably likely to predict clinical benefit” in DMD patients, the FDA said in a statement—not on proven clinical improvements. In a small clinical trial, 25 patients on Vyondys 53 saw 1.02% of normal dystrophin production after 48 weeks of treatment, up from 0.1% at baseline.

Expand

I now believe anything could happen … now if it were to happen fast …

MSB Price at posting: $1.72 Sentiment: Buy Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

There are more pages in this discussion • 6,580 more messages in this thread...

First 11683 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.52		Change 0.028(1.85%)		Mkt cap ! $1.741B

Open	High	Low	Value	Volume
$1.57	$1.58	$1.41	$15.89M	10.59M

Buyers (Bids)

No.	Vol.	Price($)
23	66822	$1.52

Sellers (Offers)

Price($)	Vol.	No.
$1.52	32219	25

View Market Depth

No.	Vol.	Price($)
12	9515	1.520
14	109170	1.515
9	122572	1.510
9	63871	1.505
7	69634	1.500

Price($)	Vol.	No.
1.525	38505	11
1.530	46949	12
1.535	177485	5
1.540	137348	14
1.545	117028	8

Last trade - 15.13pm 07/10/2024 (20 minute delay)

MSB (ASX) Chart

I now believe anything could happen … now if it were to happen...

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I now believe anything could happen … now if it were to happen...

Top Stories

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News